Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monoclonal antibody therapy.

Deirdre O'Mahony1, Michael R Bishop

  • 1Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|December 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026
Same author

Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026
Same author

CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026
Same author

Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction.

Transplantation and cellular therapy·2026
Same author

Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy.

Cancer immunology research·2026

Monoclonal antibody therapy, a targeted cancer treatment, leverages immune responses and direct cell signaling for efficacy. Approved by the FDA, these therapies are significantly impacting various cancers.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Cancer pathogenesis understanding led to targeted therapy concepts.
  • Monoclonal antibodies (mAbs) activate host defense mechanisms like antibody-dependent cytotoxicity and complement-mediated cytotoxicity.

Purpose of the Study:

  • To review and discuss US Food and Drug Administration (FDA)-approved monoclonal antibodies for cancer management.
  • To explore the mechanisms of action and therapeutic potential of mAbs in oncology.

Main Methods:

  • Review of FDA-approved monoclonal antibodies for cancer treatment.
  • Discussion of the biological pathways targeted by mAbs.
  • Analysis of therapeutic efficacy, including single-agent and combination therapies.

Main Results:

Related Experiment Videos

  • Monoclonal antibody therapy demonstrates efficacy through multiple pathways beyond immune activation, including apoptotic signaling and growth inhibition.
  • Conjugation with radionuclides or toxins offers additional therapeutic strategies.
  • Initial data shows efficacy for single-agent use, with combination therapy showing potential for greater benefit.

Conclusions:

  • Monoclonal antibody therapy is significantly impacting the management of both solid and hematological malignancies.
  • Understanding of cancer biology is crucial for developing effective targeted antibody therapies.
  • FDA-approved mAbs represent a vital class of drugs in modern cancer treatment.